Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

"Fee Matrix" Will Determine Device Civil Money Penalties - Draft Guidance

This article was originally published in The Gray Sheet

Executive Summary

FDA's draft policy on civil monetary penalties (CMPs) under the Safe Medical Devices Act of 1990 includes a "fee matrix" to help insure the consistency of assessments against chronic and repeat violators of the agency's good manufacturing procedures and premarket notification regulations.
Advertisement

Related Content

FDA Revision Of "Fee Matrix" For Civil Money Penalties Requested By HIMA
FDA Revision Of "Fee Matrix" For Civil Money Penalties Requested By HIMA
FDA's Draft Civil Money Penalty Reduction Policy Needs Clarifications - HIMA
FDA's Draft Civil Money Penalty Reduction Policy Needs Clarifications - HIMA
Advertisement
UsernamePublicRestriction

Register

MT011902

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel